Ahmad Anis, Bano Uzma, Gondal Murtaza, Khan Amna
Department of Surgery, Fauji Foundation Hospital, Rawalpindi.
J Coll Physicians Surg Pak. 2009 May;19(5):297-9.
To assess the frequency of Her-2/neu gene amplification in breast cancer and its association with clinicopathologic characteristics of the disease.
Cross-sectional comparative study.
Study was carried out at Surgical Unit I, Holy Family Hospital, Rawalpindi, from January 2005 to December 2006.
A total of 50 patients diagnosed of having breast cancer on biopsy of breast lump were included in the study. All patients underwent mastectomy and samples were submitted to AFIP (Armed Forces Institute of Pathology, Rawalpindi) for histopathology and determination of estrogen and progesterone receptors and Her-2/neu gene amplification. Moreover, association of Her-2/neu amplification to other characteristics like tumour size, node involvement, histological grade and presence of estrogen and progesterone receptors were also studied.
Out of 50 patients, 18 (36%) were positive for Her-2/neu overexpression. Among the various prognostic factors, age showed a statistically significant relation to Her-2/neu positivity (p=0.001). The Her-2/neu positive cancers were larger in size (mean size of 7.9 +/- 3.615 and 5.4 +/- 1.906 cm in Her-2/neu positive and negative cases respectively; p=0.002). Her-2/neu positive cases had statistically significant relation to number of involved lymph nodes (mean number of 9.9 and 4.4 lymph nodes in Her-2/neu positive and negative cases respectively; p=0.001). Tumour grade and nuclear grade had no statistically significant relation to Her-2/neu status (p=0.19 and 0.434 respectively). Both estrogen and progesterone receptors are inversely related to Her-2/neu positivity (p=0.028 and 0.006 respectively).
The pathological and clinical characteristics of Her-2/neu positive and negative subsets differ, and Her-2/neu overexpression was associated with other poor prognostic factors of age, tumour size and number of nodes involved. There was an inverse relation of Her-2/neu status and hormone receptor.
评估乳腺癌中Her-2/neu基因扩增的频率及其与该疾病临床病理特征的关联。
横断面比较研究。
2005年1月至2006年12月在拉瓦尔品第圣家医院外科一组开展研究。
本研究纳入了50例经乳腺肿块活检确诊为乳腺癌的患者。所有患者均接受了乳房切除术，并将样本提交给拉瓦尔品第武装部队病理研究所（AFIP）进行组织病理学检查以及雌激素和孕激素受体测定和Her-2/neu基因扩增检测。此外，还研究了Her-2/neu扩增与肿瘤大小、淋巴结受累情况、组织学分级以及雌激素和孕激素受体的存在等其他特征之间的关联。
50例患者中，18例（36%）Her-2/neu过表达呈阳性。在各种预后因素中，年龄与Her-2/neu阳性呈统计学显著相关（p=0.001）。Her-2/neu阳性的癌症体积更大（Her-2/neu阳性和阴性病例的平均大小分别为7.9±3.615 cm和5.4±1.906 cm；p=0.002）。Her-2/neu阳性病例与受累淋巴结数量具有统计学显著关系（Her-2/neu阳性和阴性病例的平均淋巴结数量分别为9.9个和4.4个；p=0.001）。肿瘤分级和核分级与Her-2/neu状态无统计学显著关系（分别为p=0.19和0.434）。雌激素和孕激素受体均与Her-2/neu阳性呈负相关（分别为p=0.028和0.006）。
Her-2/neu阳性和阴性亚组的病理和临床特征不同，Her-2/neu过表达与年龄、肿瘤大小和受累淋巴结数量等其他不良预后因素相关。Her-2/neu状态与激素受体呈负相关。
